retatrutide fda approval status as of october 2025 The has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational This weight-loss drug hasn't been

The most detailed published percentages still come from the 48-week Phase 2 trial, while the TRIUMPH Phase 3 program is the source researchers are watching for larger-sample confirmation of common adverse events, discontinuation rates, and rare safety signals

It is similar in structure to growth hormone-releasing hormone (GHRH)

Keeping momentum, CPG vet Tracey Warner Halama will step into the CEO role, replacing founder Marc Washington, who will move to executive chairman

This minimally invasive treatment targets inflammation and discomfort caused by arthritis, injury, tendonitis, or degenerative joint conditions

This may be uncomfortable at first, but it often improves over time as the body adjusts